Spark Therapeutics (Spark Therapeutics) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics 3-Year FCF Growth Rate?

Spark Therapeutics's Free Cash Flow per Share for the three months ended in Sep. 2019 was $-0.67.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Competitive Comparison of Spark Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Spark Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spark Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spark Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Spark Therapeutics's 3-Year FCF Growth Rate falls into.

Spark Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Spark Therapeutics (NAS:ONCE) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Spark Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Spark Therapeutics (Spark Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104

Website

http://www.sparktx.com

Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.

Executives

Elliot Sigal	director
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster	officer: CHIEF FINANCIAL OFFICER	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga	officer: Chief Business Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth	director, officer: CHIEF SCIENTIFIC OFFICER	334 CR 692, BUFFALO GAP TX 79508
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd	10 percent owner	ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High	director, officer: See Remarks	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey	officer: Chief Operating Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio	officer: Chief Commercial Officer	225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju	10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025